Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
复制标题
DOI：
10.1016/j.pvr.2016.03.002
复制
发表时间：
2016-12-01
影响因子：
3.2
通讯作者：
Velicer, Christine
中科院分区：
文献类型：
--
作者：
Castellsague, Xavier;Ault, Kevin A.;Velicer, Christine
背景资料：我们估计了宫颈上皮内瘤变（CIN）病例的比例归因于14种HPV类型，包括四价（qHPV）（6/11/16/18）和9价（9vHPV）（6/11/16/18/31/33/45/52/58）疫苗类型，按地区方法：来自5个地区的15-26岁和24-45岁的妇女参加qHPV疫苗临床试验。在10，706名女性（安慰剂组）中，1539名CIN 1，945名CIN 2/3和24名原位腺癌（AIS）病例由病理小组共识诊断。结果：主要HPV类型为16/51/52/56（肛门生殖器感染），16/39/51/52/56（CIN 1）和16/31/52/58（CIN 2/3）。在样本量最大的地区，在CIN 1（类似于50%）和CIN 2/3（81-85%）中观察到9vHPV类型患病率的最小区域差异。在拉丁美洲和欧洲，31/33/45/52/58型占CIN 1的25-30%，但在北美和亚洲占14-18%。在拉丁美洲（年轻女性）、欧洲和亚洲，31/33/45/52/58型占CIN 2/3的33-38%，但在拉丁美洲（老年女性）和北美占CIN 2/3的17-18%。非疫苗HPV 35/39/51/56/59型在CIN 1中的流行率与qHPV相似或高于qHPV，占CIN 2/3的2-11%。结论：9vHPV疫苗可预防大多数CIN 1 -3，不受地理区域的影响。尽管如此，非疫苗类型35/39/51/56/59仍然可能导致一些CIN 1，以及较小程度的CIN 2/3。(C)2016作者由爱思唯尔公司出版。这是一篇开放获取的文章，获得了CC BY-NC-ND许可证（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by regionMethods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus.Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (similar to 50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3.Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).